Nektar Therapeutics

Yuan Song

Antoni Kozlowski

Jennifer A Riggs-Sauthier

YongQi Mu

Xiaoming Shen

Mei-chang Kuo

Tacey Viegas

Neel Kumar Anand

Bo-Liang Deng

Timothy A Riley

Zhongxu Ren

David Lechuga-Ballesteros

Pankaj Sharma

Natalia Aurrecoechea

Donogh John Roger O'Mahony

Xuyuan Gu

Hema Gursahani

Chester Leach

Xuejun Yuan

Vijay Kumar Khatri

Michael Lixin Shen

Aleksandrs Odinecs

C Simone Jude-Fishburn

C Simone Fishburn

Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a drug-polymer conjugate, wherein the drug-polymer conjugate has a net hydrophilic character and a weight average molecular weight of from about 50 to about 20,000 Daltons, and wherein the half-life of elimination from the lung of the drug-polymer conjugate is at least about 1.5-fold greater than the half-life of elimination from the lung of the drug, wherein the half-life of elimination from the lung is measured by bronchioalveolar lavage followed by assaying residual lung material.

Chemically modified small molecules

The instant disclosure relates to (among other things) compounds that are derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine. The compounds provided possess unique effects and differences over other phenyltriazines known in the art.

Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine

Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a drug-polymer conjugate, wherein the drug-polymer conjugate has a net hydrophilic character and a weight average molecular weight of from about 50 to about 20,000 Daltons, and wherein the half-life of elimination from the lung of the drug-polymer conjugate is at least about 1.5-fold greater than the half-life of elimination from the lung of the drug, wherein the half-life of elimination from the lung is measured by bronchoalveolar lavage followed by assaying residual lung material.

Growing community of inventors

Belmont, CA, United States of America

Yuan Song